INCY Incyte
Mid-teens growth and net cash roughly cover the Jakafi cliff; fairly priced unless mutCALR delivers.
The story
Incyte is a net-cash, R&D-heavy biotech whose cash engine is Jakafi (ruxolitinib), which loses US exclusivity around 2028. It is diversifying through Opzelura, Niktimvo, Monjuvi and a mutant-CALR/JAK2V617F pipeline. TTM revenue of about $6.0B shows the commercial base is still growing at mid-teens. The life-cycle question is whether newer franchises can fill the Jakafi cliff before margins compress.
I kept all previous drivers because the facts confirm the story rather than change it. TTM revenue is up about 17% versus FY, and the 13.3% TTM margin reflects lumpy in-licensing and IPR&D charges, not lost economics; normalized margins have run around 30%. The 8-year horizon and 31% target margin still price in a Jakafi erosion that partly offsets pipeline growth, and the net cash of $3.1B adds about $15 per share.
Value drivers
| Revenue growth (Y1) | 12.0% |
| Terminal growth | 2.0% |
| Forecast horizon | 8y |
| Target operating margin | 31.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.13 |
| Beta | 1.05 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.9% |
| Terminal WACC | 9.7% |
Valuation bridge
| PV of explicit FCFF | 6.60B |
| PV of terminal value | 12.87B |
| Equity value | 22.12B |
| ÷ shares → per share | $108.52 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 6.73B | 12.0% | 16.8% | 875.74M | 638.31M | 237.43M | 216.08M |
| 2 | 7.44B | 10.6% | 20.4% | 1.17B | 629.80M | 542.38M | 449.24M |
| 3 | 8.12B | 9.1% | 23.9% | 1.50B | 602.27M | 899.58M | 678.11M |
| 4 | 8.75B | 7.7% | 27.5% | 1.86B | 554.63M | 1.30B | 893.73M |
| 5 | 9.30B | 6.3% | 31.0% | 2.23B | 486.78M | 1.74B | 1.09B |
| 6 | 9.75B | 4.9% | 31.0% | 2.34B | 399.79M | 1.94B | 1.10B |
| 7 | 10.09B | 3.4% | 31.0% | 2.42B | 295.91M | 2.12B | 1.10B |
| 8 | 10.29B | 2.0% | 31.0% | 2.47B | 178.54M | 2.29B | 1.08B |
Key risks
- Jakafi generic erosion from 2028 is steeper than Opzelura/Niktimvo growth can offset
- mutCALR antibody and JAK2V617F programs fail or slip, leaving no second franchise
- Continued expensive BD and IPR&D charges that permanently depress margins and destroy capital
Catalysts
- Proof-of-concept and registrational data for the mutCALR antibody (INCA033989) in MPNs
- Opzelura label expansions (pediatric AD, HS, prurigo) and Jakafi XR lifecycle extension